Mutually exclusive mutations of the Pten and ras pathways in skin tumor progression
AUTOR(ES)
Mao, Jian-Hua
FONTE
Cold Spring Harbor Laboratory Press
RESUMO
Pten heterozygous (Pten+/-) mice develop increased papilloma numbers and show decreased carcinoma latency time in comparison with controls after skin treatment with dimethyl benzanthracene (DMBA) and tetradecanoyl-phorbol acetate (TPA). H-ras mutation is normally a hallmark of DMBA-TPA-induced skin tumors, but 70% of carcinomas from Pten+/- mice do not exhibit this mutation, and in all cases have lost the wild-type Pten allele. Tumors that retain the Pten wild-type allele also have H-ras mutations, indicating that activation of H-ras and complete loss of Pten are mutually exclusive events in skin carcinomas. Mitogen-activated protein kinase (MAPK) is consistently activated in the tumors with H-ras mutations, but is strongly down-regulated in Pten-/- tumors, suggesting that this pathway is dispensable for skin carcinoma formation. These data have important implications in designing individual therapeutic strategies for the treatment of cancer.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=517400Documentos Relacionados
- Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression.
- Mutually exclusive synthetic pathways for sea urchin mitochondrial rRNA and mRNA.
- Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
- Mutually exclusive groups of bronchitics and non-bronchitics in males
- Mutually Exclusive Utilization of PR and PRM Promoters in Bacteriophage 434 OR
